Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ C7orf60 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA565637
Description
Immunogen sequence: QERKLEQEKLS GVVKSVHRRL RKKYREVGDF DKIWREHCED EETLCEYAVA MKNLADNHWA KTCEGEGRIE WCCSVCREYF Q Highest antigen sequence identity to the following orthologs - mouse 99%, rat 38%.
S-adenosyl-L-methionine-binding protein that acts as an inhibitor of mTORC1 signaling via interaction with the GATOR1 and KICSTOR complexes (PubMed:29123071). Acts as a sensor of S-adenosyl-L-methionine to signal methionine sufficiency to mTORC1: in presence of methionine, binds S-adenosyl-L-methionine, leading to disrupt interaction with the GATOR1 and KICSTOR complexes and promote mTORC1 signaling (PubMed:29123071). Upon methionine starvation, S-adenosyl-L-methionine levels are reduced, thereby promoting the association with GATOR1 and KICSTOR, leading to inhibit mTORC1 signaling (PubMed:29123071). Probably also acts as a S-adenosyl-L-methionine-dependent methyltransferase (Potential). [UniProt].
Specifications
C7orf60 | |
Polyclonal | |
Unconjugated | |
BMT2 | |
base methyltransferase of 25S rRNA 2 homolog; BMT2; C7orf60; Probable methyltransferase BMT2 homolog; probable methyltransferase BTM2 homolog; S-adenosylmethionine sensor upstream of mTORC1; SAMTOR; UPF0532 protein C7orf60 | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
154743 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunocytochemistry | |
0.10 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q1RMZ1 | |
BMT2 | |
Recombinant Human C7orf60. Recombinant protein control fragment (Product #RP-106306). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction